Skip to main content

Monte Rosa Therapeutics, Inc.

GLUE
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001826457

In the last 90 days, Monte Rosa Therapeutics, Inc. insiders filed 0 open-market purchases and 3 sales; 192 institutions reported holding it in 13F filings for Q2 2026, worth $2.24B in total; Duquesne Family Office is the only superinvestor holding it.

Q2 2023 vs. Q1 2023

How the institutions holding Monte Rosa Therapeutics, Inc. changed between Q1 2023 and Q2 2023.

All holders in Q2 2023All holders in Q1 2023

13F holders of GLUE: Q1 2023 compared with Q2 2023
MeasureQ1 2023Q2 2023Change
Holders6968−1
Shares39.8M39.7M−23.0K (−0.1%)
Value$309.8M$272.3M−$37.5M (−12.1%)

New holders (9)

Institutions that held Monte Rosa Therapeutics, Inc. at the end of Q2 2023 but not at the end of Q1 2023.

Institutions new to GLUE in Q2 2023
InstitutionSharesValue% of portfolio
Candriam Luxembourg S.C.A.135,000$924.8K0.01%
Janus Henderson Group PLC23,792$163.0K0.00%
Exchange Traded Concepts, LLC20,996$143.8K0.00%
Octagon Capital Advisors LP19,900$136.3K0.02%
Bank of Montreal11,379$99.2K0.00%
American Century Companies Inc12,935$88.6K0.00%
Connor, Clark & Lunn Investment Management Ltd.12,458$85.3K0.00%
Arizona State Retirement System11,785$80.7K0.00%
Teacher Retirement System of Texas11,313$77.0K0.00%

Sold out (10)

Institutions that held Monte Rosa Therapeutics, Inc. at the end of Q1 2023 and filed for Q2 2023 without it.

Institutions that sold out of GLUE in Q2 2023
InstitutionShares, Q1 2023Value, Q1 2023
Cormorant Asset Management, LP2,893,717$22.5M
Millennium Management LLC117,094$912.0K
Squarepoint Ops LLC13,998$109.0K
SG Americas Securities, LLC13,411$104.0K
Susquehanna International Group, LLP13,111$102.1K
Jane Street Group, LLC12,349$96.2K
Principal Financial Group Inc11,395$88.8K
Ameriprise Financial Inc10,955$85.3K
Two Sigma Investments, LP10,100$78.7K
Nisa Investment Advisors, LLC2,190$17.0K